JERUSALEM, June 10, 2013 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a clinical-stage developer of oral delivery systems, announced today that it has been invited to present at the 12th National Life Science & Technology Week IATI-BioMed Conference taking place from June 10-12, 2013, in Tel Aviv, Israel. Josh Hexter, Oramed's Chief Operating Officer and Vice President of Business Development, will present on Tuesday, June 11th at 3:10 PM.
IATI-BioMed 2013 follows the success of previous annual conferences where the Israeli Life Science Industry (ILSI) hosted 6,000 industry players, engineers and scientists with approximately 1,000 participants from over 40 countries, and in excess of 3,500 one-on-one meetings.
The IATI-BioMed conference, formerly known as the ILSI-BioMed Conference, is Israel's premier life science conference showcasing the country's most advanced companies and technologies. Building on the great reputation established in previous years, IATI-BioMed offers attendees and presenters a winning mix of industry keynote speakers, exciting and innovative company presentations, and three days of exhibition and networking opportunities. In addition, the Academic Institution's Technology Transfer offices and scientists from Israel's universities and healthcare institutions are present throughout the event.
For more information on the IATI-BioMed conference, the content of which is not part of this press release, please visit: http://www2.kenes.com/biomed/Pages/Home.aspx
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and diabetic patients (Phase 2a) underway. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit http://www.oramed.com
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss revolutionizing the treatment of diabetes with our products, or when we discuss our clinical trials. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
SOURCE Oramed Pharmaceuticals Inc.